4Bio Capital, of London, appointed Brian P. McVeigh venture partner.
Akari Therapeutics plc, of London, appointed Torsten Hombeck chief financial officer.
Arcturus Therapeutics Holdings Inc., of San Diego, appointed Jeff Colyer, Ooi Eng Eong, Frederick G. Hayden, Peter A. Patriarca, Robert T. Schooley and Jonathan Smith to its vaccine platform scientific advisory board.
Beigene Ltd., of Beijing, appointed Angus Grant chief business executive.
Cellectar Biosciences Inc., of Florham Park, N.J., appointed John Friend chief medical officer.
Codiak Biosciences Inc., of Cambridge, Mass., appointed Yalonda Howze executive vice president, chief legal officer.
Egenesis Inc., of Cambridge, Mass., appointed Peter Hanson chief operating officer.
Khondrion BV, of Nijmegen, the Netherlands, appointed Herma Renkema chief early development officer.
Moderna Inc., of Cambridge, Mass., appointed Elizabeth Tallett to its board.
Scenic Biotech BV, of Amsterdam, appointed C. A. Oscar Izeboud CEO and Sebastian Nijman chief scientific officer.
Sotio AS, of Prague, Czech Republic, appointed Richard Sachse chief medical officer.
Trevi Therapeutics Inc., of New Haven, Conn., elected Dominick C. Colangelo to its board.
Xoma Corp., of Emeryville, Calif., appointed Natasha A. Hernday to its board.
Zentalis Pharmaceuticals Inc., of New York, appointed Kimberly Blackwell to its board.